Repaglinide (Repaglinide)
Overview of Repaglinide
Repaglinide is oral hypoglycemic agent. The onset of action is rapid but the duration of action is short. Repaglinide is used in the treatment of non-insulin dependent diabetes. It may also reduce the long term cardiovascular, cerebrovascular and renal effects of diabetes.
Indication of Repaglinide
Repaglinide is primarily indicated in conditions like NIDDM, Type II diabetes mellitus.
Contraindication of Repaglinide
Repaglinide is contraindicated in conditions like Coma,Diabetic ketoacidosis.
Side Effects of Repaglinide
The signs and symptoms that are produced after the acute overdosage of Repaglinide include Nausea, Convulsions, Coma, Seizures, Sweating, Cerebral damage.,The symptomatic adverse reactions produced by Repaglinide are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Diarrhea, Anaphylactoid reactions, Constipation, Allergy, Nausea and vomiting, Thrombocytopenia, Chest pain, Bronchitis, Sinusitis, Hypoglycemia.
Precautions of Repaglinide
Use with caution in patients with hepatic impairment. All oral hypoglycemic agents are capable of producing hypoglycemia. Proper patient selection, dosage and the instruction to the patients are important to avoid hypoglycemic episodes. It may be necessary to discontinue repaglinide and administer insulin if the patient is exposed to stress (fever, trauma, infection, surgery). At higher dosages sulfonylurea may block the ATP-sensitive potassium channel, which may correspond to an increase risk of cardiovascular events. Avoid the use of sulfonylurea at higher dosages (repaglinide daily doses >1.5 mg).